Skip to main content
Medical information Clinical review pending

Genetic Testing

SDHA Gene Paragangliomas Type 5 Genetic Test

The SDHA Gene Paragangliomas Type 5 NGS Genetic DNA Test identifies mutations in the SDHA gene linked to paragangliomas. This test helps assess genetic risk for early detection and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SDHA Gene Paragangliomas Type 5 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal or family history of paragangliomas
  • ✓Suspicion of hereditary paraganglioma syndromes
  • ✓Presence of symptoms potentially related to paragangliomas
  • ✓Genetic counseling for individuals with relevant family history
  • ✓Confirmation of diagnosis in suspected cases
02

In plain language

What this test helps you understand

Identifies mutations in the SDHA gene associated with paragangliomas, aiding in risk assessment and management.
The SDHA Gene Paragangliomas Type 5 NGS Genetic DNA Test uses Next-Generation Sequencing (NGS) technology to analyze your genetic material. It is designed to identify specific mutations within the SDHA gene. These mutations are associated with an increased risk of developing paragangliomas, which are tumors that can arise in different parts of the body. Understanding your genetic predisposition through this test can provide valuable information for your health management and potential treatment options.

This test focuses specifically on detecting alterations in the SDHA gene. This gene is important for how cells produce energy. Changes in this gene can disrupt normal cell function and contribute to the formation of paragangliomas. Early detection of these genetic changes is important for effective management.

Individuals with a family history of paragangliomas or related conditions may benefit from this test. Symptoms that might suggest the need for testing include unexplained tumors or growths, a known family history of SDHA mutations, or symptoms commonly associated with paragangliomas, such as persistent headaches, excessive sweating, or heart palpitations. Discussing your personal and family medical history with your doctor is crucial to determine if this test is appropriate for you.

Taking this test offers several potential benefits, including the early identification of a genetic predisposition to paragangliomas. This knowledge can empower you and your healthcare provider to make informed decisions about appropriate health surveillance and management strategies. It may also contribute to developing personalized treatment plans if needed and can provide peace of mind for you and your family.

Results will be provided in a clear format. A genetic counselor is available to help interpret the findings, explain their implications for your health, and discuss any recommended follow-up steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the SDHA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations in the SDHA gene. It does not detect all possible genetic causes of paragangliomas or other conditions. Results should be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

A paraganglioma is a type of tumor that develops from paraganglia cells, which are found throughout the body. They can occur in various locations, such as the head, neck, chest, or abdomen.
Individuals with a personal or family history of paragangliomas, or those experiencing symptoms potentially related to these tumors, should discuss this test with their doctor.
The test involves analyzing a sample of your blood (DNA) to look for specific changes (mutations) in the SDHA gene.
Results are interpreted by genetic experts and counselors. They will explain the findings, their potential implications, and any recommended next steps.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp